SKI-178 is primarily investigated for its potential in cancer treatment due to its ability to inhibit sphingosine kinase 1 (SphK1), an enzyme involved in cancer cell survival and proliferation. By targeting SphK1, it may help reduce tumor growth and enhance the effectiveness of chemotherapy. Additionally, it is being studied for its role in modulating inflammatory responses, which could have implications in treating inflammatory diseases. Research is ongoing to explore its therapeutic potential in various conditions, including solid tumors and hematologic malignancies.